


I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9307 on 9/26/02

TOWNSEND and TOWNSEND and CROW LLP

By: 

PATENT
Attorney Docket No.: 15270J-004741US
Client Ref. No.: 209-US-CIP5C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/723,713

Filed: November 27, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Sharon Turner

Art Unit: 1647

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This paper is being submitted in response to the Office Action mailed March 26, 2002. A petition to extend the time to respond for three months, from June 26, 2002 to September 26, 2002 is submitted herewith. Please amend the above-identified application as follows.

IN THE SPECIFICATION:

Please replace the paragraph beginning at line 25 of page 14 with the following replacement paragraph.

Polyclonal sera typically contain mixed populations of antibodies binding to several epitopes along the length of A β . Monoclonal antibodies bind to a specific epitope within A β that can be a conformational or nonconformational epitope. Some monoclonal antibodies bind to an epitope within residues 1-28 of A β (with the first N terminal residue of natural A β designated 1). Some monoclonal antibodies bind to an epitope with residues 1-10 of A β . Some monoclonal antibodies bind to an epitope with residues 1-16 of A β . Some monoclonal